One explanation for the lower prevalence in our cohort was that patients with a high chance of an EGFR mutation (e.g. adenocarcinoma and never smokers) might have had a prior local testing10, and only those with negative local testing or in the unusual event of no testing for EGFR being available were included in SPECTA4,11. The gene discussed is EGFR; the disease is adenocarcinoma.